RPTX Valuation

Repare Therapeutics Inc

Add to Watchlist

Advanced Chart

1.560

+0.01(0.645%)1D

Overview
Forecast
Valuation
Earnings

RPTX Relative Valuation

RPTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RPTX is overvalued; if below, it's undervalued.

Historical Valuation

Repare Therapeutics Inc (RPTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.65 is considered Undervalued compared with the five-year average of -6.57. The fair price of Repare Therapeutics Inc (RPTX) is between 1.96 to 2.96 according to relative valuation methord. Compared to the current price of 1.55 USD , Repare Therapeutics Inc is Undervalued By 21.06%.

Relative Value

Fair Zone

1.96-2.96

Current Price：1.55

21.06%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.53

P/B

Median3y

1.19

Median5y

2.16

-179.07

FCF Yield

Median3y

-56.77

Median5y

-36.64

Competitors Valuation Multiple

The average P/S ratio for RPTX's competitors is 15.73, providing a benchmark for relative valuation. Repare Therapeutics Inc Corp (RPTX) exhibits a P/S ratio of 6.56, which is -58.28% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RPTX.O

Repare Therapeutics Inc

6.56

Average P/S: 15.73

-100.00%